PT-141 is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
PT-141 (Bremelanotide) is researched primarily for increased sexual desire in premenopausal women, improved sexual arousal, non-hormonal sexual enhancement. One of the few FDA-approved peptide therapies and the only medication targeting sexual desire through melanocortin brain pathways rather than vascular mechanisms — treats desire itself, not just physical function. It belongs to the Melanocortin receptor agonist category of compounds.
What Is PT-141?
PT-141 (Bremelanotide) is a Melanocortin receptor agonist. Synthetic α-MSH analog targeting MC1R and MC4R for sexual desire modulation.
One of the few FDA-approved peptide therapies and the only medication targeting sexual desire through melanocortin brain pathways rather than vascular mechanisms — treats desire itself, not just physical function. It has attracted significant research interest for its potential effects on increased sexual desire in premenopausal women, improved sexual arousal, non-hormonal sexual enhancement.
How Does PT-141 Produce These Benefits?
Activates melanocortin receptors MC1R and MC4R, with MC4R modulating sexual desire through hypothalamic neural circuits. Engages endogenous melanocortin pathways regulating arousal, desire, and sexual response — a completely different mechanism than PDE5 inhibitors like sildenafil.
This multi-pathway activity is why PT-141 shows potential across several different applications rather than being limited to a single use case.
Can PT-141 Help With Increased Sexual Desire In Premenopausal Women?
Research suggests PT-141 may support increased sexual desire in premenopausal women through its melanocortin receptor agonist activity. FDA approved in 2019 based on two Phase 3 trials with 1,267+ premenopausal women showing significant improvements in sexual desire and reduced distress. Well-established safety and efficacy profile.
Protocols targeting increased sexual desire in premenopausal women typically use 1.75 mg per dose (FDA-approved) administered on-demand, 45 minutes before anticipated activity; maximum 8 doses per month for on-demand acute dosing; no continuous cycle required.
Can PT-141 Help With Improved Sexual Arousal?
Research suggests PT-141 may support improved sexual arousal through its melanocortin receptor agonist activity. FDA approved in 2019 based on two Phase 3 trials with 1,267+ premenopausal women showing significant improvements in sexual desire and reduced distress. Well-established safety and efficacy profile.
Protocols targeting improved sexual arousal typically use 1.75 mg per dose (FDA-approved) administered on-demand, 45 minutes before anticipated activity; maximum 8 doses per month for on-demand acute dosing; no continuous cycle required.
Can PT-141 Help With Non-Hormonal Sexual Enhancement?
Research suggests PT-141 may support non-hormonal sexual enhancement through its melanocortin receptor agonist activity. FDA approved in 2019 based on two Phase 3 trials with 1,267+ premenopausal women showing significant improvements in sexual desire and reduced distress. Well-established safety and efficacy profile.
Protocols targeting non-hormonal sexual enhancement typically use 1.75 mg per dose (FDA-approved) administered on-demand, 45 minutes before anticipated activity; maximum 8 doses per month for on-demand acute dosing; no continuous cycle required.
Can Stacking Enhance PT-141 Benefits?
Works through a unique mechanism distinct from PDE5 inhibitors; not typically combined with other sexual enhancement agents.
See our PT-141 stacking guide for detailed combination protocols.
What Is the Bottom Line on PT-141 Benefits?
PT-141 is researched for increased sexual desire in premenopausal women, improved sexual arousal, non-hormonal sexual enhancement. The evidence base includes: FDA approved in 2019 based on two Phase 3 trials with 1,267+ premenopausal women showing significant improvements in sexual desire and reduced distress. Well-established safety and efficacy profile.
PT-141 is fda-approved (2019) as vyleesi for hypoactive sexual desire disorder in premenopausal women. prescription medication. off-label use for males by some providers. Source from reputable vendors with third-party testing for reliable results.
Complete Guide
PT-141 (Bremelanotide): Research
Related Reading
- PT-141 Dosage Guide
- PT-141 Side Effects
- PT-141 Stacking Guide
- PT-141 Cycle Guide
- PT-141 Research
- ARA-290 Complete Guide
Calculate Your PT-141 Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for PT-141.
Open Calculator →Research-Grade Sourcing
If you're going to research PT-141, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is PT-141?
PT-141 (Bremelanotide) is a Melanocortin receptor agonist. Synthetic α-MSH analog targeting MC1R and MC4R for sexual desire modulation. It is researched for increased sexual desire in premenopausal women, improved sexual arousal, non-hormonal sexual enhancement.
What is the recommended PT-141 dosage?
Common dosages: 1.75 mg per dose (FDA-approved) administered on-demand, 45 minutes before anticipated activity; maximum 8 doses per month via subcutaneous self-injection. Cycle length: on-demand acute dosing; no continuous cycle required. Half-life: peak effects 15-30 minutes post-injection. Use our peptide calculator for exact reconstitution math.
What are the side effects of PT-141?
Nausea (40% incidence, especially first injection), flushing (20%), injection site reactions (13%), headache (11%). Transient blood pressure increases (2-3 mmHg average). Contraindicated in uncontrolled hypertension.
Is PT-141 safe?
PT-141 has shown a preliminary safety profile in research. FDA-approved (2019) as Vyleesi for hypoactive sexual desire disorder in premenopausal women. Prescription medication. Off-label use for males by some providers. All research should follow appropriate safety protocols.